From Medscape Oncology

Coverage from the

European Hematology Association (EHA) 2022 Annual Meeting

June 09 - 12, 2022; Vienna, Austria and Virtual/Online

June 09 - 12, 2022 Vienna, Austria and Virtual/Online

EHA 2022 Similar Survival, Less Toxicity With Decitabine vs Chemo in AML For patients with acute myeloid leukemia, treatment with decitabine prior to stem cell transplantation had similar overall survival and much less toxicity compared with intensive chemotherapy.
Medscape Medical News, June 12, 2022
EHA 2022 A New First-line Regimen for Advanced Hodgkin Lymphoma? Patients receiving brentuximab vedotin plus chemotherapy demonstrated a significant improvement in overall survival at 6 years compared with those on standard chemotherapy.
Medscape Medical News, June 10, 2022

Conference News

EHA 2022 Zanubrutinib-Obinutuzumab Doubles PFS in Follicular Lymphoma
Medscape Medical News, June 17, 2022
EHA 2022 New CAR-T Therapy Elicits Strong Response in Multiple Myeloma
Medscape Medical News, June 16, 2022
EHA 2022 Venetoclax Combos Improve Progression-Free Survival in CLL
Medscape Medical News, June 15, 2022
EHA 2022 New Therapy May Offer 'Functional Cure' for Two Blood Disorders
Medscape Medical News, June 14, 2022

EHA 2022 Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML
Medscape Medical News, June 13, 2022
EHA 2022 Similar Survival, Less Toxicity With Decitabine vs Chemo in AML
Medscape Medical News, June 12, 2022
EHA 2022 A New First-line Regimen for Advanced Hodgkin Lymphoma?
Medscape Medical News, June 10, 2022
EHA 2022 Severe COVID-19 and Blood Cancer: Plasma Therapy May Help
Medscape Medical News, June 10, 2022

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Advances in Thrombosis and Hemostasis From EHA 2022
Benjamin Brenner, MD

Popular News from EHA 2021

'Impressive Results' With CAR T-cell in R/R Follicular Lymphoma Updated results show that patients who received the novel CAR T-cell therapy had significantly improved overall survival than comparable patients who received other current therapies.
Medscape Medical News, Jun 15, 2021
Zanubrutinib Better Than Ibrutinib in CLL/SLL? An interim phase 3 clinical trial analysis shows encouraging progression-free survival and lower cardiac toxicity in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Medscape Medical News, Jun 13, 2021
Multiple Myeloma Highlights From EHA 2021 Prof Pieter Sonneveld discusses the latest advances in multiple myeloma from EHA 2021, including novel immune approaches, management of newly diagnosed disease, and options for high-risk patients.
Medscape Medical News, Jul 7, 2021

Previous Coverage